Incyte

Stories

Epcoritamab plus R-CHOP halves progression risk in first-line lymphoma trial

Competitor; Monjuvi (tafasitamab) in first-line DLBCL

AbbVie and Genmab reported on October 5 that adding epcoritamab to the R-CHOP chemotherapy combination cut the risk of disease progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma. It is the first phase 3 trial of a bispecific antibody, a drug that steers the body's T cells onto cancer cells, to beat the 20-year-old R-CHOP backbone.

Updated Oct 24

Pfizer's oral drug restores skin pigment in vitiligo trials

New Capabilities

As of August 2026: Maker of the only approved repigmentation drug

For most of medical history, vitiligo had no fix. Doctors could sometimes slow the spreading white patches, but regrowing lost skin color was mostly out of reach.

Updated Aug 5